BDD Completes Successful Dosing of all Patients, on Schedule, in Head-to-Head Clinical Study of Investigational Subcutaneous Furosemide (SQIN-Furosemide)

BDD Completes Successful Dosing of all Patients, on Schedule, in Head-to-Head Clinical Study of Investigational Subcutaneous Furosemide (SQIN-Furosemide) GLASGOW, Scotland, Feb. 17, 2026 BDD & SQinnovation today announced all patients have been successfully dosed on schedule, at BDD’s phase 1 clinic in Glasgow, Scotland – in a head-to-head clinical study evaluating SQIN-furosemide, an investigational subcutaneous formulation of furosemide, versus the commercially available furosemide solution for intravenous infusion (Lasix®). The study is designed to compare the bioavailability, pharmacokinetics (PK) and pharmacodynamics (PD) of SQIN-furosemide against the intravenous comparator, generating additional clinical evidence to support the programme’s continued development and planned regulatory discussions in Europe. Furosemide is a well-established medicine used worldwide to help manage fluid overload in heart failure, by increasing urine output to remove excess salt and water. While furosemide is commonly administered orally or intravenously, SQIN-furosemide has been developed to enable subcutaneous administration (into the fatty tissue just beneath the skin). This approach has the potential to support treatment outside of hospital, including at-home management, with the aim of helping reduce avoidable admissions for patients experiencing worsening congestion. Dr Lyn Corry, Principal Investigator at BDD, said: “Dosing our first participant is an important milestone for this programme. We look forward to generating robust comparative PK/PD data from this study and supporting the team as they advance SQIN-furosemide through its next stages of development.” About the study This head-to-head clinical study is comparing SQIN-furosemide with intravenously administered furosemide (Lasix®) and assess bioavailability, PK and PD to better characterise the performance of the novel subcutaneous formulation. About BDD BDD Pharma Ltd is an integrated UK-based clinical research organisation whose Lean Clinical Development™ pathway combines formulation development, GMP manufacturing and Phase I clinical studies to help accelerate product development. For further information, contact: BDD Pharma Ltd. Tel: +44 (0)141 552 8791 Email: [email protected] Website: bddpharma.com World Class Drug Delivery Company Glasgow Royal Infirmary 84 Castle St Glasgow G4 0SF, UK +44 (0)141 552 8791 Bio-City Scotland Bo’ness Road Chapelhall, Newhouse ML1 5UH, UK +44 (0)141 404 9540 © Copyright 2026 BDD Ltd Registered in Scotland No. 212868 Privacy Policy Acceptable Use Terms of Use Website design by Genetic Digital

The release as fetched from its publisher. bddpharma.com ↗